On January 8, 1974, plaintiff Stanley Sanders instituted this class action pursuant to Rule 23 of the Federal Rules of Civil Procedure under § 22 of the Securities Act of 1933 (“Act”), 15 U.S.C. § 77v, to enforce a liability created by §§ 11 & 12(2) of the Act, 15 U.S.C. §§ 77k and 111. The gravamen of the complaint against the defendant Faraday Laboratories, Inc., (“Faraday”) and the other defendants is that plaintiff and others similarly situated purchased shares of Faraday’s common stock in reliance upon a registration statement filed August 10, 1971 and the prospectus issued thereunder,
On November 16, 1978 — four years and eleven months after the action was instituted — plaintiff moved under Fed.R.Civ.P. 23(c)(1) to have this action certified as a class action. Although the parties admit that discovery proceedings are now practically completed, plaintiff has served only a limited number of interrogatories since the filing of the complaint'and has conducted only one deposition which was not noticed until November 1978. Defendants oppose the motion on two principal grounds: (1) that plaintiff cannot represent the class because he has suffered no damages under the cause of action stated, and (2) that plaintiff’s failure to seek class certification until almost five years after filing of the complaint and his failure to vigorously prosecute the action render him an inadequate class representative.
DISCUSSION
Fed.R.Civ.P. 23(a) provides, in pertinent part, as follows:
One or more members of a class may sue . as representative parties on behalf of all only if . (3) the claims or defenses of the representative parties are typical of the claims or defenses of the class, and (4) the representative parties will fairly and adequately protect the interests of the class.
The claims of the representative of the class must, of course, be typical of those of the class, but we do not believe that plaintiff’s inability to prove damages reflects adversely upon the typicality of his claim or his ability to adequately represent and protect the interests of the other class members. Numerous decisions in this Circuit and elsewhere have properly focussed on the typicality of a plaintiff’s claim as it applies to the general liability issues rather than on the plaintiff’s ultimate ability to recover. Mersay v. First Republic Corp. of America,
There is little doubt that Rule 23 does not require a court to adjudicate the merits of a plaintiff’s claim to certify a class. Such an interpretation of Rule 23 has been rejected by the United States Supreme Court in Eisen v. Carlisle and Jacquelin,
Defendants’ second contention, however, raises a more serious issue. Subdivision (c) of Rule 23 describes the time frame in which the question of class certification should be considered, and it provides that “[a]s soon as practicable after the com
Even assuming, as a number of courts have held, that a district judge has an obligation on his own motion to determine whether an action shall proceed as a class action, (citations omitted), the named plaintiffs’ failure to protect the interests of class members by moving for certification surely bears strongly on the adequacy of the representation that those class members might expect to receive. Plaintiff’s delay in seeking class certification has been recognized as an important factor in considering a motion for class certification. In re Value Line Special Situations Fund Litigation; Mendelsohn v. Arnold Bernhard and Co., [1975] Fed.Sec.L. Rep. (CCH) ¶ 94,954 (S.D.N.Y.1975); Adise v. Mather,
We recognize the general principle that delay in seeking certification should not, absent other compelling circumstances, result in denial of certification. Feder v. Harrington,
Finally, we note that denial of this motion does not cause the proposed class members’ claims to be time barred if they desire to prosecute their claims with another representative. As stated in American Pipe and Construction Co. v. Utah,
Accordingly, plaintiff’s motion for certification of the class is hereby denied.
SO ORDERED.
Notes
. The prospectus covered 160,000 shares of common stock, of which plaintiff purchased approximately 3,275. Prior to initiation of this action, plaintiff sold 1,975 of those shares.
. In April 1972, the Food and Drug Administration (“FDA”) made symbolic seizures of OVA II and commenced an action in the United States District Court for the District of New Jersey, claiming that defendant Faraday had an obligation to have the product registered as a drug. In July 1975, the district court found that the product was not a drug and that the FDA seizure was unjustified. United States v. An Article of Drug OVA II,
. According to defendants, the shares were offered to the public at $5 per share pursuant to the Registration Statement; plaintiff purchased 3,275 shares at an average cost of $23.68 per share and a total cost of $77,544.55; and plaintiff sold all but 1300 of the shares for $68,-430.00 at an average price per share of $34.65. Defendants contend that § 11(e) of the Securities Act of 1933 (“Act”), 15 U.S.C. § 77k(e), limits the damages a plaintiff may recover to the price at which the shares were offered to the public and, therefore, that plaintiff has already recouped more than he would be entitled to recover should he be able to establish liability of the defendants. Because we find that the question of individual damages does not affect plaintiffs qualifications to represent the class as to liability, it is unnecessary for us to consider these contentions at the present time.
. Plaintiff’s counsel states in his brief and supporting affidavit that at a conference with the Court which occurred “I believe in 1975,” it was his “recollection that the scheduling of a
. The class was described in U 25 of the complaint as “all customers of Flaks, Zaslow who purchased the common stock of Faraday that was the subject of the aforementioned registration statement . ” In the instant motion plaintiff seeks to include “all purchasers of the common stock of Faraday Laboratories, Inc., who purchased the shares that were the subject of the August 1971 Registration Statement of Faraday Laboratories, Inc., who purchased their shares between August 10, 1971 and August 9, 1974.”
